P259 Effects of metformin on clinical outcome in patients hospitalised for COPD exacerbations: a retrospective cohort study

Hitchings, Andrew W.; Hayes, Lee; Picton, Graham; Turner, Lesley; Cull, R E; Aslam, Shamaila; Archer, John R. H.; Srivastava, Salil; Baker, EH

doi:10.1136/thoraxjnl-2011-201054c.259

Cited by 1 publication

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As Kim et al (20) expanded the OHA according to our selection criteria, we eventually excluded their report from this study. Finally, six articles (involving 3,467 participants) were included in our review: one was an RCT (15), four were retrospective studies (13,(21)(22)(23) (three were published as abstracts) and the last ( 14) was…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Role of metformin in treatment of patients with chronic obstructive pulmonary disease: a systematic review

Zhu¹,

Teng²,

Ge³

et al. 2019

J. Thorac. Dis.

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is commonly associated with type 2 diabetes mellitus (T2DM). Metformin is a first-line treatment for most patients with T2DM, and may have antiaging, antioxidant, and anti-tumour effects. A few published studies report the use of metformin for the treatment of COPD in patients with or without T2DM, but the results are inconsistent. This study aimed to confirm the effectiveness and safety of metformin as a treatment option in patients with COPD. We performed a systematic search of PubMed, EMBASE, and the Cochrane database from their starting date to December 2017. Randomised controlled trials (RCTs), controlled clinical trials, and retrospective researches reporting the use of metformin for treating patients with COPD were identified. We included a total of six articles (involving 3,467 participants) and found that metformin may benefit patients with COPD and T2DM by improving health status and symptoms, hospitalisations, and mortality. There was no effect on patients with COPD without T2DM. Metformin causes minimal increases in plasma lactate concentrations without lactic acidosis and has little impact on blood glucose and minor adverse events. Metformin is safe and effective for treating COPD in patients with concomitant T2DM.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Four articles (13,15,21,23) Lactic acidosis, defined as a lactate concentration of ≥5 mmol/L was not reported. All of the above indicated that there were no significant differences between the two groups.…”

Section: Lactate Concentrationmentioning

confidence: 99%